CHIT1 and metabolic dysfunction-associated steatohepatitis: This indicates that CHIT1 inhibition can effectively shift metabolism towards a more energetic state, which can be beneficial for the treatment of metabolic disorders, as proven by drugs like metformin or the newly FDA-registered drug for MASH, resmetirom (82, 83).